Optimizing dendritic cell function by genetic modification

Journal of the National Cancer Institute

Volumn 92, Issue 15, 2000, Pages 1198-1199

  Lyerly, H Kim ^a   Clay, Tim ^a   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL HETEROGENEITY; CELL MATURATION; CELL MIGRATION; DENDRITIC CELL; DNA MODIFICATION; EDITORIAL; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 0034596312     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.15.1198     Document Type: Editorial

References (8)

1. Immunobiology of dendritic cells
2. Dendritic cells in cancer immunotherapy
3. Clinical applications of dendritic cell vaccines
4. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules
5. Immunotherapy of cancer with dendritic-cell-based vaccines
6. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
7. Migration of human dendritic cells after injection in patients with metastatic malignancies
8. A subset of human monocyte derived dendritic cells express high levels of IL-12 in response to combined CD40 ligand and IFN-gamma treatment